Remove tag medicines-lifecycle
article thumbnail

Pioneering the Path Pre- and Post-Launch Strategies

PM360

It covers the product lifecycle in its entirety by delivering innovative approaches to anticipate and address the needs of patients, healthcare providers, and payers alike. Making the Case for Early Medical Affairs Involvement Early involvement of Medical Affairs in the product lifecycle is not just beneficial—it is mission critical.

Medical 52
article thumbnail

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity. However, not all innovations are equal and nor do they follow a constant upward trend.

article thumbnail

Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs

PM360

This option grows more critical as new therapies become available with price tags as high as $3.5 Many new solutions allow the high one-time costs of gene therapies and other expensive medication to be converted into small, predictable payments over time for payers. million for the new hemophilia gene therapy.